Literature DB >> 23759437

Imaging characteristics of neovascular pigment epithelial detachments and their response to anti-vascular endothelial growth factor therapy.

Omar S Punjabi1, Joyce Huang, Lina Rodriguez, Alice T Lyon, Lee M Jampol, Rukhsana G Mirza.   

Abstract

PURPOSE: To evaluate the imaging characteristics of macular neovascular pigment epithelial detachments (PEDs) and their response to anti-vascular endothelial growth factor (VEGF) therapy.
METHODS: Patients with exudative age-related macular degeneration (AMD), idiopathic polypoidal choroidal vasculopathy, presumed ocular histoplasmosis syndrome (POHS) and central serous retinopathy (CSR) with choroidal neovascularisation (CNV) were included in the study. A retrospective chart review of 72 eyes of 64 patients was performed.
RESULTS: Three types of PEDs were identified based on reflectivity of the material under the retinal pigment epithelium on optical coherence tomography: hollow (26 eyes with primarily hyporeflectivity under the PED), solid (30 eyes with primarily hyperreflective signal under the PED) and mixed (8 eyes with mixed reflectivity). The average number of anti-VEGF injections was 7 per eye and the average duration of follow-up was 16 months. Among eyes with exudative AMD, 7/21 hollow PEDs flattened, 1/19 solid PEDs flattened and 2/6 mixed PEDs flattened after anti-VEGF therapy. POHS and CSR with CNV were associated with subfoveal solid PEDs and were unchanged after therapy. Overall, 46% (12/26) with hollow PEDs, 25% (2/8) with mixed PEDs and 3% (1/30) with solid PEDs had flattening after anti-VEGF therapy.
CONCLUSIONS: The likelihood of PED flattening was inversely related to the reflectivity of the PED. The more reflective the PED, the less likely resolution with anti-VEGF therapy occurred.

Entities:  

Keywords:  Imaging; Macula; Retina

Mesh:

Substances:

Year:  2013        PMID: 23759437     DOI: 10.1136/bjophthalmol-2013-303155

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  7 in total

1.  Multispectral imaging in detecting early retinal pigment epithelial atrophy.

Authors:  Jie Zhang; Ying-Bai Chen; Zi-Kui Yu; Lin Liu
Journal:  Int J Ophthalmol       Date:  2018-06-18       Impact factor: 1.779

2.  Intravitreal aflibercept in treatment-resistant pigment epithelial detachment.

Authors:  Ibrahim Kocak
Journal:  Int Ophthalmol       Date:  2016-07-21       Impact factor: 2.031

3.  Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration.

Authors:  Zongyi Wang; Mengyang Li; Yuou Yao; Jie Hu; Jiyang Tang; Ran Tang; Zhenyu Piao; Jinfeng Qu
Journal:  J Ophthalmol       Date:  2020-09-07       Impact factor: 1.909

4.  Morphologic Criteria of Lesion Activity in Neovascular Age-Related Macular Degeneration: A Consensus Article.

Authors:  Stefania Miotto; Nicola Zemella; Elena Gusson; Giacomo Panozzo; Sandro Saviano; Giuseppe Scarpa; Giorgio Boschi; Stefano Piermarocchi
Journal:  J Ocul Pharmacol Ther       Date:  2017-11-17       Impact factor: 2.671

5.  Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept.

Authors:  Pallavi Tyagi; Zain Juma; Yong Keen Hor; Neil W Scott; Andreea Ionean; Cynthia Santiago
Journal:  BMC Ophthalmol       Date:  2018-06-22       Impact factor: 2.209

6.  Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.

Authors:  Magda Gharbiya; Ludovico Iannetti; Francesco Parisi; Umberto De Vico; Maria Laura Mungo; Marco Marenco
Journal:  Biomed Res Int       Date:  2014-05-07       Impact factor: 3.411

7.  Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.

Authors:  C R Clemens; F Alten; J Termühlen; N Mihailovic; F Rosenberger; P Heiduschka; N Eter
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-04-18       Impact factor: 3.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.